- Home
- RFI vs LRMR Comparison
RFI vs LRMR Comparison
Compare RFI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- LRMR
- Stock Information
- Founded
- RFI 1992
- LRMR N/A
- Country
- RFI United States
- LRMR United States
- Employees
- RFI N/A
- LRMR N/A
- Industry
- RFI Investment Managers
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- LRMR Health Care
- Exchange
- RFI Nasdaq
- LRMR Nasdaq
- Market Cap
- RFI 313.7M
- LRMR 332.1M
- IPO Year
- RFI N/A
- LRMR N/A
- Fundamental
- Price
- RFI $11.14
- LRMR $3.39
- Analyst Decision
- RFI
- LRMR Strong Buy
- Analyst Count
- RFI 0
- LRMR 7
- Target Price
- RFI N/A
- LRMR $16.71
- AVG Volume (30 Days)
- RFI 69.8K
- LRMR 1.5M
- Earning Date
- RFI 01-01-0001
- LRMR 11-05-2025
- Dividend Yield
- RFI 8.25%
- LRMR N/A
- EPS Growth
- RFI N/A
- LRMR N/A
- EPS
- RFI N/A
- LRMR N/A
- Revenue
- RFI N/A
- LRMR N/A
- Revenue This Year
- RFI N/A
- LRMR N/A
- Revenue Next Year
- RFI N/A
- LRMR N/A
- P/E Ratio
- RFI N/A
- LRMR N/A
- Revenue Growth
- RFI N/A
- LRMR N/A
- 52 Week Low
- RFI $9.62
- LRMR $1.61
- 52 Week High
- RFI $12.52
- LRMR $6.91
- Technical
- Relative Strength Index (RSI)
- RFI 26.88
- LRMR 40.97
- Support Level
- RFI $11.40
- LRMR $3.32
- Resistance Level
- RFI $11.68
- LRMR $3.64
- Average True Range (ATR)
- RFI 0.13
- LRMR 0.28
- MACD
- RFI -0.03
- LRMR -0.01
- Stochastic Oscillator
- RFI 5.78
- LRMR 22.40
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.